{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:27:56Z","timestamp":1786357676842,"version":"build-2736575974"},"reference-count":65,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Glioblastoma multiforme (GBM) is the most common brain tumor in the adult population, and it is characterized by poor prognosis; thus, new treatment strategies are strongly needed. Precision medicine is a rapidly growing field in oncology that identifies specific molecular features of tumor cells and allows theranostic strategies (combining diagnosis and therapy). In nuclear medicine, prostate-specific membrane antigen (PSMA) represents an interesting molecular target in theranostics, considering its involvement in the neoangiogenesis of many kinds of tumors, including GBM. In this narrative review, we performed a web-based literature search to explore the current evidence regarding PSMA-targeted nuclear medicine theranostics in GBM, highlighting diagnostic applications, therapeutic potential, and future clinical perspectives.<\/jats:p>","DOI":"10.3390\/ijms27167112","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:24:53Z","timestamp":1786353893000},"page":"7112","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA-Targeted Theranostics in Glioblastoma Multiforme: Current Evidence and Future Perspectives"],"prefix":"10.3390","volume":"27","author":[{"given":"Francesca","family":"Russo","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit, St. Salvatore Hospital, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9277-6337","authenticated-orcid":false,"given":"Maria","family":"Ricci","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Cardarelli Hospital, 86100 Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habibollah","family":"Dadgar","sequence":"additional","affiliation":[{"name":"Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad 9198613636, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7413-5897","authenticated-orcid":false,"given":"Laura","family":"Travascio","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Spirito Santo Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3216-4838","authenticated-orcid":false,"given":"Maria Silvia","family":"De Feo","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Brunotti","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, St. Salvatore Hospital, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9274-7571","authenticated-orcid":false,"given":"Sharjeel","family":"Usmani","sequence":"additional","affiliation":[{"name":"Sultan Qaboos Comprehensive Care and Research Centre, University Medical City, Muscat 5661, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6526-0960","authenticated-orcid":false,"given":"Hossein","family":"Arabi","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Medical Imaging, Geneva University Hospital, CH-1211 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah M.","family":"Anwar","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Warith International Cancer Institute, Karbala 56001, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysar Najeh","family":"Khalaf","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Warith International Cancer Institute, Karbala 56001, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-5496","authenticated-orcid":false,"given":"Luca","family":"Filippi","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome \u2018Tor Vergata\u2019, Via Montpellier 1, 00133 Rome, Italy"},{"name":"Nuclear Medicine Research Unit, IRCCS San Raffaele Roma, Via della Pisana 235, 00163 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0533-2947","authenticated-orcid":false,"given":"Andrea","family":"Cimini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, St. Salvatore Hospital, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lan, Z., Li, X., and Zhang, X. (2024). Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25053040"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","article-title":"Glioblastoma multiforme: Insights into pathogenesis, key signaling pathways, and therapeutic strategies","volume":"24","author":"Pouyan","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cimini, A., Ricci, M., Chiaravalloti, A., Filippi, L., and Schillaci, O. (2020). Theragnostic aspects and radioimmunotherapy in pediatric tumors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113849"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cimini, A., Ricci, M., Russo, F., Egidi, M., Calabria, F., Bagnato, A., Schillaci, O., and Chiaravalloti, A. (2021). Peptide receptor radionuclide therapy and primary brain tumors: An overview. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090872"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/annonc\/mdx106","article-title":"Glioblastoma targeted therapy: Updated approaches from recent biological insights","volume":"28","author":"Touat","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","article-title":"Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme","volume":"135","author":"Wernicke","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1097\/RLU.0000000000001487","article-title":"PSMA expression in tumor neovasculature endothelial cells of follicular thyroid adenoma as identified by molecular imaging using 68Ga-PSMA ligand PET\/CT","volume":"42","author":"Derlin","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_8","first-page":"482","article-title":"Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers","volume":"122","author":"Wernicke","year":"2014","journal-title":"J. Pathol. Microbiol. Immunol."},{"key":"ref_9","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res."},{"key":"ref_10","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","article-title":"New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy","volume":"22","author":"Haberkorn","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lauri, C., Chiurchioni, L., Russo, V.M., Zannini, L., and Signore, A. (2022). PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216590"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/abr.abr_209_18","article-title":"Prostate-specific membrane antigenexpression in neovasculature of glioblastoma multiforme","volume":"8","author":"Shavakhi","year":"2019","journal-title":"Adv. Biomed. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Holzgreve, A., Biczok, A., Ruf, V.C., Liesche-Starnecker, F., Steiger, K., Kirchner, M.A., Unterrainer, M., Mittlmeier, L., Herms, J., and Schlegel, J. (2021). PSMA expression in glioblastoma as a basis for theranostic approaches: A retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.646387"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1128\/MCB.00084-06","article-title":"Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction","volume":"26","author":"Conway","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Moreau, A., Febvey, O., Mognetti, T., Frappaz, D., and Kryza, D. (2019). Contribution of different positron emission tomography tracers in glioma management: Focus on glioblastoma. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01134"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gao, Y., Zheng, H., Li, L., Feng, M., Chen, X., Hao, B., Lv, Z., Zhou, X., and Cao, Y. (2021). Prostate-specific membrane antigen (PSMA) promotes angiogenesis of glioblastoma through interacting with ITGB4 and regulating NF-\u03baB signaling pathway. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.598377"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Truckenmueller, P., Graef, J., Scheel, M., Vajkoczy, P., Capper, D., Kaul, D., Furth, C., Amthauer, H., Brenner, W., and Onken, J.S. (2022). [68Ga] Ga-PSMA PET\/MRI, histological PSMA expression and preliminary experience with [177Lu]Lu-PSMA therapy in relapsing high-grade glioma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.980058"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate-specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases","volume":"14","author":"Nomura","year":"2014","journal-title":"Cancer Cell Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.30699\/ijp.13.1.45","article-title":"Expression of prostate-specific membrane antigen (PSMA) in brain glioma and its correlation with tumor grade","volume":"13","author":"Saffar","year":"2018","journal-title":"Iran. J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mvr.2006.03.004","article-title":"Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: Implications for targeting to tumor vasculature","volume":"72","author":"Anilkumar","year":"2006","journal-title":"Microvasc. Res."},{"key":"ref_22","first-page":"1349","article-title":"Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium","volume":"38","author":"Liu","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1541-7786.MCR-16-0193","article-title":"Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment","volume":"14","author":"Nguyen","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1101\/gad.300079.117","article-title":"Glioblastoma cellular cross-talk converges on NF-\u03baB to attenuate EGFR inhibitor sensitivity","volume":"31","author":"Zanca","year":"2017","journal-title":"Genes Dev."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Grant, C.L., Caromile, L.A., Ho, V., Durrani, K., Rahman, M.M., Claffey, K.P., Fong, G.H., and Shapiro, L.H. (2012). Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS ONE, 7, Correction in PLoS ONE 2012, 7.","DOI":"10.1371\/journal.pone.0041285"},{"key":"ref_26","unstructured":"Stefanik, D. (2013). Vascular endothelial growth factor in malignant disease of the central nervous system. Madame Curie Bioscience Database, Landes Bioscience."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","article-title":"Joint ANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: Version 1.0","volume":"46","author":"Law","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/RLU.0000000000001451","article-title":"Diagnostic value of 68Ga-PSMA-11 PET\/CT imaging of brain tumors: Preliminary analysis","volume":"42","author":"Sasikumar","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20220049","DOI":"10.1259\/bjr.20220049","article-title":"Is there any additional benefit of ^68Ga-PSMA PET on radiotherapy target volume definition in patients with glioblastoma?","volume":"95","author":"Akgun","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/RLU.0000000000002806","article-title":"68Ga-Prostate-Specific Membrane Antigen-11 PET\/CT: A new imaging option for recurrent glioblastoma multiforme?","volume":"45","author":"Kunikowska","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109199","DOI":"10.1016\/j.ejrad.2020.109199","article-title":"68Ga PSMA PET\/MR in the differentiation of low and high grade gliomas: Is 68Ga PSMA PET\/MRI useful to detect brain gliomas?","volume":"130","author":"Akgun","year":"2020","journal-title":"Eur. J. Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00432-025-06184-z","article-title":"PSMA PET\/CT for prostate cancer diagnosis: Current applications and future directions","volume":"151","author":"Shen","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00259-019-04477-3","article-title":"Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET","volume":"46","author":"Vettermann","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11060-018-2825-5","article-title":"Potential use of prostate-specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody","volume":"138","author":"Matsuda","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101548","DOI":"10.1016\/j.adro.2024.101548","article-title":"Comparative analysis of recurrent glioblastoma target contours via 11C-methionine, 68Ga-prostate-specific membrane antigen positron emission tomography, and magnetic resonance imaging: Implications for precision radiotherapy planning","volume":"9","author":"Ferini","year":"2024","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhang, H., Koumna, S., Pouliot, F., Beauregard, J.M., and Kolinsky, M. (2021). PSMA theranostics: Current landscape and future outlook. Cancers, 13.","DOI":"10.3390\/cancers13164023"},{"key":"ref_38","first-page":"417","article-title":"Secreted phosphoprotein 1 promotes angiogenesis of glioblastoma through upregulating PSMA expression via transcription factor HIF1\u03b1","volume":"55","author":"Tu","year":"2023","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2967\/jnumed.125.270987","article-title":"Quantitative comparison of SPECT and PET performance for clinical theranostic applications","volume":"67","author":"Salerno","year":"2026","journal-title":"J. Nucl. Med."},{"key":"ref_40","first-page":"41","article-title":"Usefulness of SPECT\/CT with a hybrid camera for the functional anatomical mapping of primary brain tumors by [Tc99m] tetrofosmin","volume":"21","author":"Filippi","year":"2006","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00234-026-04042-4","article-title":"Diagnostic accuracy of [99mTc]-Tc-HYNIC-PSMA-11 SPECT\/CT in differentiating tumor recurrence from post-treatment changes in glioblastoma","volume":"68","author":"Ghaedian","year":"2026","journal-title":"Neuroradiology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2967\/jnumed.123.265738","article-title":"PET imaging and protein expression of prostate-specific membrane antigen in glioblastoma: A multicenter inventory study","volume":"64","author":"Pruis","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00259-020-04715-z","article-title":"Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","article-title":"Advances in local therapy for glioblastoma: Taking the fight to the tumour","volume":"18","author":"Nieland","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1097\/RLU.0000000000003142","article-title":"177Lu-\/68Ga-PSMA theranostics in recurrent glioblastoma multiforme: Proof of concept","volume":"45","author":"Kumar","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/RLU.0000000000005904","article-title":"Excellent response of glioblastoma multiforme to [177Lu] Lu-PSMA therapy","volume":"51","author":"Ghaedian","year":"2026","journal-title":"Clin. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1097\/RLU.0000000000005904","article-title":"Safety and feasibility of [177Lu] Lu-PSMA therapy in glioblastoma","volume":"51","author":"Ghaedian","year":"2026","journal-title":"Clin. Nucl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.122.264850","article-title":"[177Lu] Lu-PSMA therapy as an individual treatment approach for patients with high-grade glioma: Dosimetry results and critical statement","volume":"64","author":"Graef","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Pinkiewicz, M., Pinkiewicz, M., Walecki, J., and Zawadzki, M. (2022). A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.950167"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1097\/RLU.0000000000002280","article-title":"Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in cerebral radionecrosis: Implications for diagnostic imaging of high-grade gliomas","volume":"43","author":"Pienta","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"105068","DOI":"10.1016\/j.ebiom.2024.105068","article-title":"Potential of PSMA-targeting radioligand therapy for malignant primary and secondary brain tumours using super-selective intra-arterial administration: A single-centre, open-label, non-randomised prospective imaging study","volume":"102","author":"Pruis","year":"2024","journal-title":"EBioMedicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1148\/radiol.2433060536","article-title":"Complications of diagnostic cerebral angiography: Evaluation of 19,826 consecutive patients","volume":"243","author":"Kaufmann","year":"2007","journal-title":"Radiology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00259-021-05196-4","article-title":"CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor\/[177Lu]Lu-Pentixather","volume":"49","author":"Jacobs","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dadgar, H., Jokar, N., Nemati, R., Larvie, M., and Assadi, M. (2023). PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach. Front. Nucl. Med., 3.","DOI":"10.3389\/fnume.2023.1103262"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Serumula, W., Pillay, V., Hadebe, B., and Vorster, M. (2025). Fibroblast activation protein inhibitor (FAPI)-based theranostics. Pharmaceuticals, 18.","DOI":"10.3390\/ph18040522"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Bailly, C., Vidal, A., Bonnemaire, C., Kraeber-Bod\u00e9r\u00e9, F., Ch\u00e9rel, M., Pallardy, A., Rousseau, C., Garcion, E., Lacoeuille, F., and Hindr\u00e9, F. (2019). Potential for nuclear medicine therapy for glioblastoma treatment. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00772"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s10147-025-02777-3","article-title":"The curse of blood-brain barrier and blood-tumor barrier in malignant brain tumor treatment","volume":"30","author":"Kawauchi","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14737140.2024.2398492","article-title":"Intra-arterial administration of PSMA-targeted radiopharmaceuticals for brain tumors: Is the era of interventional theranostics next?","volume":"24","author":"Filippi","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kauffman, N., Morrison, J., O\u2019Brien, K., Fan, J., and Zinn, K.R. (2023). Intra-arterial delivery of radiopharmaceuticals in oncology: Current trends and the future of alpha-particle therapeutics. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041138"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.7150\/thno.106081","article-title":"Current Landscape and Future Directions of Targeted-Alpha-Therapy for Glioblastoma Treatment","volume":"15","author":"Roncali","year":"2025","journal-title":"Theranostics"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI Procedure Guideline for the Use of 177Lu-Labeled PSMA-Targeted Radioligand Therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.7150\/thno.107963","article-title":"Targeted Radioligand Therapy: Physics and Biology, Internal Dosimetry and Other Practical Aspects during 177Lu\/225Ac Treatment in Neuroendocrine Tumors and Metastatic Prostate Cancer","volume":"15","author":"Dadgar","year":"2025","journal-title":"Theranostics"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Brighi, C., Puttick, S., Woods, A., Keall, P., Tooney, P.A., Waddington, D.E.J., Sproule, V., Rose, S., and Fay, M. (2023). Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as imaging biomarkers in adult recurrent glioblastoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216208"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sabuzi, F., Filippi, L., Trulli, M., Domenici, F., Garaci, F., and Da Ros, V. (2026). Intra-arterial radioligand therapy in brain cancer: Bridging nuclear medicine and interventional neuroradiology. Diagnostics, 16.","DOI":"10.3390\/diagnostics16020341"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Civelek, A.C. (2026). PSMA-based radiopharmaceuticals in prostate cancer theranostics: Imaging, clinical advances, and future directions. Cancers, 18.","DOI":"10.3390\/cancers18020234"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7112\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:29:31Z","timestamp":1786354171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":65,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167112"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167112","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]}}}